Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia
Genes · 2023
DOI: 10.3390/genes14010153 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Genes, 2023. Verfasst von Holm Schneider und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Ectodermal Dysplasias and Department of Pediatrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 …. Hauptthemen laut MEDLINE: Ectodermal Dysplasia 1, Anhidrotic, Ectodermal Dysplasia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry for Education and Research (BMBF), EspeRare Foundation.
Abstract (Originalsprache)
X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare genetic disorder characte-rised by abnormal development of the skin and its appendages, such as hair and sweat glands, the teeth, and mucous glands of the airways, resulting in serious, sometimes life-threatening complications like hyperthermia or recurrent respiratory infections. It is caused by pathogenic variants of the ectodysplasin A gene (EDA). Most affected males are hemizygous for EDA null mutations that lead to the absence or inactivity of the signalling protein ectodysplasin A1 (EDA1) and, thus, to the full-blown phenotype with inability to perspire and few if any teeth. There are currently no long-term treatment options for XLHED. ER004 represents a first-in-class protein replacement molecule designed for specific, high-affinity binding to the endogenous EDA1 receptor (EDAR). Its proposed mechanism of action is the replacement of missing EDA1 in yet unborn patients with XLHED. Once bound to EDAR, ER004 activates the EDA/NFκB signalling pathway, which triggers the transcription of genes involved in the normal development of multiple tissues. Following preclinical studies, named-patient use cases demonstrated significant potential of ER004 in affected males treated in utero during the late second and third trimesters of pregnancy. In order to confirm these results, we started the EDELIFE trial, a prospective, open-label, genotype-match controlled, multicentre clinical study to investigate the efficacy and safety of intra-amniotic ER004 administration as a prenatal treatment for male subjects with XLHED. This article summarises the rationale, the study protocol, ethical issues of the trial, and potential pitfalls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Ectodermal Dysplasias and Department of Pediatrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
- Department of Dermatology, Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hospitals of Paris, University of Paris-Cité, 75743 Paris,…
- Department of Obstetrics and Gynecology, University Hospital Erlangen, 91054 Erlangen, Germany.
- Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University, St. Louis, MO 63110, USA.
- Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA 94143, USA.
- Pediatric Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, 20122 Milan, Italy.
ORCID-Profile: Angus Clarke, Athmane Bouroubi, Florence Porte
Förderung
- German Federal Ministry for Education and Research (BMBF)
- EspeRare Foundation
Zitieren
APA
Schneider, H., Hadj-Rabia, S., Faschingbauer, F., Bodemer, C., Grange, D. K., Norton, M. E., Cavalli, R., Tadini, G., Stepan, H., Clarke, A., Guillén-Navarro, E., Maier-Wohlfart, S., Bouroubi, A., & Porte, F. (2023). Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes. https://doi.org/10.3390/genes14010153
Vancouver
Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Norton ME, et al. Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes. 2023. doi:10.3390/genes14010153
BibTeX
@article{Schneider2023,
author = {Schneider, Holm and Hadj-Rabia, Smail and Faschingbauer, Florian and Bodemer, Christine and Grange, Dorothy K and Norton, Mary E and Cavalli, Riccardo and Tadini, Gianluca and Stepan, Holger and Clarke, Angus and Guillén-Navarro, Encarna and Maier-Wohlfart, Sigrun and Bouroubi, Athmane and Porte, Florence},
title = {Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14010153}
}
EUVIMED